견적문의

TOKYO--( / )--Toshiba Electronic Devices & Storage Corporation (“Toshiba”) has today started to supply “TMPM3HQFDFG” microcontroller for use in general-purpose MCU boards manufactured by Thundersoft, a Chinese platform technology provider that designs, manufactures and develops circuits and platforms for devices, including smart devices.

TMPM3HQFDFG is an Arm® Cortex®-M core-based microcontroller in the TXZ™ family’s “M3H group” developed for consumer and industrial equipment.

In recent years, methods for rapid system prototyping have advanced by combining microcontroller boards with commercially available function boards. Thundersoft’s general-purpose MCU board integrating TXZ™ family microcontrollers is compatible with the Arm Mbed™ OS. Customers can start development immediately after the introduction of the MCU board, using an on-line compiler and other development environments provided free of charge by Arm.

The board is also equipped with Arduino compatible connectors and SeeedGrove connectors, both widely used in the industry, and it allows rapid system development? prototyping?with numerous commercially available shields (function boards) and sensors.

Thundersoft’s general-purpose MCU boards will be available on the Taobao website in China and on the Thundersoft’s corporate website in other regions from this month.

Toshiba will support a wide range of customers in speeding up time to market for products and expand its semiconductor business by reflecting the needs of customers to its product development.

Main features of Thundersoft’s general-purpose MCU boards

· Incorporates the global standard, Arm Cortex-M core-based microcontroller TMPM3HQFDFG equipped with a wide range of peripheral circuits to enhance versatility.

· Supports diverse applications with built-in Arduino compatible connector and SeeedGrove connector

· Mbed support enables use of Arm’s development environments.

For details of TMPM3HQFDFG, please visit the following website.

For details of Thundersoft’s MCU boards, please visit the following website.

For details of Mbed, please visit the following Mbed website of Arm Ltd.

* Arm, Cortex and Mbed are registered trademarks or trademarks of Arm Limited (or its subsidiaries) in the US and/or elsewhere.

* All other company names, product names and service names may be trademarks of their respective companies.

Customer Inquiries:

Mixed Signal IC Sales and Marketing Department

Tel: +81-44-548-2876

Information in this document, including product prices and specifications, content of services and contact information, is current on the date of the announcement but is subject to change without prior notice.

About Toshiba Electronic Devices & Storage Corporation

Toshiba Electronic Devices & Storage Corporation combines the vigor of a new company with the wisdom of experience. Since becoming an independent company in July 2017, we have taken our place among the leading general devices companies, and offer our customers and business partners outstanding solutions in discrete semiconductors, system LSIs and HDD.

Our 22,000 employees around the world share a determination to maximize the value of our products, and emphasize close collaboration with customers to promote co-creation of value and new markets. We look forward to building on annual sales now surpassing 800-billion yen (US$7 billion) and to contributing to a better future for people everywhere.

Find out more about us at

View source version on businesswire.com:Toshiba Brings Arm® Cortex®-M core-based Microcontrollers to Thundersoft's MCU Boards

INGELHEIM, GERMANY--( / )--The European Medicine Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended the granting 고흥홀덤펍 야마토2014 of a conditional market authorization[*] for Boehringer Ingelheim’s spesolimab as first in class treatment 연금복권추첨방송 지씨카르틴 option for generalized pustular psoriasis (GPP) flares in adults. Spesolimab, marketed in the U.S. and in Japan as SPEVIGO®, is a novel, selective antibody that blocks the 연금복권추첨방송 남성갱년기자가진단 activation of the interleukin-36 receptor (IL-36R), a signaling pathway within the immune system shown to 고흥홀덤펍 be involved in the pathogenesis of GPP.[1, 3, 연금복권추첨방송 야마토통기계버전 5]

“GPP flares are unpredictable, often require emergency care and can lead to serious, life-threatening complications 연금복권추첨방송 such 고흥홀덤펍 오리지날 as shock and multisystem organ failure,” said Herve Bachelez, M.D., Ph.D., study investigator and professor at the Department of 연금복권추첨방송 온라인릴게임정보 Dermatology of the Saint-Louis University Hospital in Paris. 연금복권추첨방송 훼라민 “The positive opinion for spesolimab brings us one step closer to a 고흥홀덤펍 음경필러시술 new and first treatment option specifically designed to target 고흥홀덤펍 인터넷릴천지 the IL-36 pathway that is central to the pathogenesis of GPP.”

“This positive recommendation recognizes spesolimab’s potential as a new targeted 연금복권추첨방송 monoclonal antibody that could treat the 연금복권추첨방송 underlying cause of GPP. The accelerated 연금복권추첨방송 황금성게임 development of spesolimab underscores our continued commitment to develop faster and more 고흥홀덤펍 트리믹스사용법 novel treatments for people with high unmet medical needs,” commented Carinne Brouillon, Member of the Board of Managing 고흥홀덤펍 덴탈리도 Directors, responsible for Human Pharma, Boehringer Ingelheim.

The 고흥홀덤펍 성기확대술 CHMP’s 연금복권추첨방송 인터넷성인릴게임 positive opinion on spesolimab is based on results 고흥홀덤펍 from the pivotal EFFISAYIL® 1 Phase II clinical trial.[1] In the 12-week trial, patients 인스타그램 검색 Thea GPP flare were treated with spesolimab or placebo. Most patients at the outset of the trial had a high, or very high, density of pustules, and impaired quality of life. After one week, 54% of patients treated with spesolimab showed no visible pustules compared to placebo (6%).[1] Adverse events were reported in 66% of patients 고흥홀덤펍 길이연장 treated with spesolimab and 56% of those receiving placebo after one week. Infections were reported by 17% and 6% of patients in the spesolimab and placebo groups respectively (at week one). Serious adverse events were reported in 6% of patients treated with spesolimab (at week one).[1]

In common with other rare diseases, people living with GPP often do not receive a correct diagnosis and their symptoms identified as other forms of psoriasis. Recently, a Global Consensus Delphi Panel of experts 연금복권추첨방송 가정상담소 concluded a systematic literature review that classified GPP as phenotypically, genetically, immunologically and histopathologically distinct from psoriasis vulgaris / plaque psoriasis. Gaining consensus on definitions, 연금복권추첨방송 diagnosis and treatment goals is 고흥홀덤펍 부부성클리닉 a positive advance to improve patient care.[2]

For 연금복권추첨방송 the 인스타그램 검색 Forpress release and link to ‘Notes to 연금복권추첨방송 예비부부교육 고흥홀덤펍 예비부부교육 Editors’ please click here:

[*] A conditional marketing authorization is granted to 연금복권추첨방송 발기부전치료법 a medicinal product that fulfils an unmet medical need when the benefit to public health of immediate availability outweighs the risk inherent in the fact 고흥홀덤펍 의처증 that additional data are still required. The marketing authorization holder is expected 연금복권추첨방송 to provide comprehensive clinical data at a later stage. In this regard, Boehringer Ingelheim will provide additional data 연금복권추첨방송 on the treatment of subsequent flares.

View source version 고흥홀덤펍 EAP on businesswire.com:Korea Newswire distributes your news across 연금복권추첨방송 가정상담센터 every media 고흥홀덤펍 조루증 channels through the 연금복권추첨방송 성문제 industry’s largest press release distribution network 연금복권추첨방송